Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371227 | 0.91 | RAB9A (0.61) | KAT2BRAB9AMAPTALDH1A1LMNA | |
| SCHEMBL6214461 | 0.90 | KAT2B (0.73) | KAT2BRAB9AGSTM2MAPTALDH1A1 | |
| SCHEMBL6220073 | 0.88 | KAT2B (0.71) | KAT2BRAB9AGSTM2MAPTALDH1A1 | |
| SCHEMBL6218547 | 0.85 | KAT2B (0.74) | KAT2BRAB9AGSTM2MAPTALDH1A1 | |
| SCHEMBL762635 | 0.85 | KAT2B (0.60) | KAT2BRAB9AMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL515537 | 0.84 | KAT2B (0.81) | KAT2BRAB9AMAPTLMNAPKM | |
| SCHEMBL740421 | 0.82 | KAT2B (0.56) | KAT2BRAB9AMAPTALDH1A1LMNA | |
| SCHEMBL28493360 | 0.81 | KAT2B (0.55) | KAT2BRAB9AMAPTALDH1A1LMNA | |
| SCHEMBL112161 | 0.80 | KAT2B (0.70) | KAT2BRAB9AMAPTALDH1A1LMNA | |
| SCHEMBL29519350 | 0.80 | KAT2B (0.70) | KAT2BRAB9AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | KAT2B 3155/4885RAB9A 3603/4885GSTM2 1222/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | KAT2B 3155/4885RAB9A 3603/4885GSTM2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.